Use of Telomerase to Create Bioengineered Tissues
The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
Abstract
Telomeres are repetitive DNA (TTAGGG) elements at the ends of chromosomes. Telomerase is a ribonucleoprotein complex that catalyzes the addition of telomeric sequences to the ends of chromosomes. The catalytic protein component of telomerase (hTERT) is expressed only in specific germ line cells, proliferative stem cells of renewal tissues, and cancer cells. The expression of hTERT in normal cells reconstitutes telomerase activity and circumvents the induction of senescence. Telomeres shorten with each cell division, eventually leading to senescence (aging), due to incomplete lagging DNA strand synthesis and end‐processing events, and because telomerase activity is not detected in most somatic tissues. There are specific tissues and locations in which replicative senescence likely contributes to the decline in human physiological function with increased age and with chronic illnesses. While expressing hTERT in cells results in the maintenance of telomere length and greatly extended life span, blocking replicative aging systemically would be predicted to increase the potential for tumor formation. However, there are many situations in which the transient rejuvenation of cells could be beneficial. Ectopic expression of hTERT has been shown to immortalize human skin keratinocytes, dermal fibroblasts, muscle satellite (stem), and vascular endothelial, myometrial, retinal‐pigmented, and breast epithelial cells. In addition, human bronchial, corneal and skin cells expressing hTERT can be used to form organotypic (3D) cultures (bioengineered tissues) that express differentiation‐specific proteins, demonstrating that hTERT by itself does not alter normal physiology. The production of hTERT‐engineered tissues offers the possibility of producing tissues to treat a variety of chronic diseases and age‐related medical conditions that are due to telomere‐based replicative senescence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Accelerated telomere shortening in response to life stress
Epel, E. S., Blackburn, E. H., Lin, J., Dhabhar, F. S., Adler, N. E., Morrow, J. D., & Cawthon, R. M. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407162101 · Cited by 3,002
A survey of telomerase activity in human cancer
Shay, J. W., & Bacchetti, S. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00062-2 · Cited by 2,794
Self-citationAssociation between telomere length in blood and mortality in people aged 60 years or older
Cawthon, R. M., Smith, K. R., O'Brien, E., Sivatchenko, A., & Kerber, R. A. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12384-7 · Cited by 1,761
Morin, G. B. (1989) · Cell · doi:10.1016/0092-8674(89)90035-4 · Cited by 1,495
Hemann, M. T., Strong, M. A., Hao, L.-Y., & Greider, C. W. (2001) · Cell · doi:10.1016/s0092-8674(01)00504-9 · Cited by 1,219
Heiss, N. S., Knight, S. W., Vulliamy, T. J., Klauck, S. M., Wiemann, S., Mason, P. J., Poustka, A., & Dokal, I. (1998) · Nature Genetics · doi:10.1038/ng0598-32 · Cited by 976
The RNA component of telomerase is mutated in autosomal dominant dyskeratosis congenita
Vulliamy, T., Marrone, A., Goldman, F., Dearlove, A., Bessler, M., Mason, P. J., & Dokal, I. (2001) · Nature · doi:10.1038/35096585 · Cited by 960
Hayflick, his limit, and cellular ageing
Shay, J. W., & Wright, W. E. (2000) · Nature Reviews Molecular Cell Biology · doi:10.1038/35036093 · Cited by 764
Self-citationMutations in TERT, the Gene for Telomerase Reverse Transcriptase, in Aplastic Anemia
Yamaguchi, H., Calado, R. T., Ly, H., Kajigaya, S., Baerlocher, G. M., Chanock, S. J., Lansdorp, P. M., & Young, N. S. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa042980 · Cited by 723
Connecting Chromosomes, Crisis, and Cancer
Maser, R. S., & DePinho, R. A. (2002) · Science · doi:10.1126/science.297.5581.565 · Cited by 561
Cited by
Paracrine Mechanisms in Adult Stem Cell Signaling and Therapy
Gnecchi, M., Zhang, Z., Ni, A., & Dzau, V. J. (2008) · Circulation Research · doi:10.1161/circresaha.108.176826 · Cited by 2,027
Le Maitre, C. L., Freemont, A. J., & Hoyland, J. A. (2007) · Arthritis Research & Therapy · doi:10.1186/ar2198 · Cited by 457
“Cellular senescence can be prevented, bypassed, or reversed in other settings and perhaps here too [35,40,41].”
Reijnders, C. M. A., van Lier, A., Roffel, S., Kramer, D., Scheper, R. J., & Gibbs, S. (2015) · Tissue Engineering Part A · doi:10.1089/ten.tea.2015.0139 · Cited by 147
“The exogenous hTERT cDNA, which encodes for the catalytic subunit of human telomerase, prevents telomere shortening and, thereby, increases the life span of the cells, while maintaining the normal physiology and phenotypic properties of the cells.(54,55) In our study, we determined whether hTERT-immortalized human new…”
BackgroundMimeault, M., & Batra, S. K. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00885.x · Cited by 38
“For instance, the use of skin stem/progenitor cells and their progenies engineering for expressing human TERT or telomere RNA component (TR) represents a therapy of great interest for treating the chronological or premature aging disorders such as Werner progenoid syndrome, Fanconi anaemia and chronic dysplastic anaem…”
BackgroundReview of hTERT-Immortalized Cells: How to Assess Immortality and Confirm Identity
Shitova, M., Alpeeva, E., & Vorotelyak, E. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms252313054 · Cited by 22
Metadata
- Authors
- SHAY, J. W., & WRIGHT, W. E.
- Venue
- Annals of the New York Academy of Sciences
- Publisher
- Wiley
- Published
- 2005-12
- Volume
- 1057
- Issue
- 1
- Pages
- 479-491
- ISSN
- 0077-8923 (ISSN-L)
- 1749-6632
- OpenAlex
- W2149000137
- Cited by
- 49
- References
- 18
- FWCI
- 1.64
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Use of Telomerase to Create Bioengineered Tissues. https://app.cochat.ai/papers/10.1196/annals.1356.037
- The paper
- SHAY, J. W., & WRIGHT, W. E. (2005). Use of Telomerase to Create Bioengineered Tissues. Annals of the New York Academy of Sciences. https://doi.org/10.1196/annals.1356.037
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.